• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Monday, November 2, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Frailty score predicts outcomes in Australian pneumonia patients, study finds

by
October 29, 2026
in Health
Reading Time: 3 mins read
0
Frailty score predicts outcomes in Australian pneumonia patients, study finds

Frailty score predicts outcomes in Australian pneumonia patients, study finds

Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Older people hospitalised with community-acquired pneumonia who score higher on a simple administrative frailty measure tend to stay in hospital longer, need intensive care more often, and are more likely to die, according to a retrospective observational study conducted at two Australian hospitals.

The study, published in the journal Aging Clinical and Experimental Research, set out to externally validate the Hospital Frailty Risk Score (HFRS) in an Australian population of patients admitted with community-acquired pneumonia, a condition that is common globally and disproportionately affects older, frailer people. The HFRS assesses frailty using routinely collected administrative data, but its performance in evaluating clinical outcomes among hospitalised Australian pneumonia patients had not previously been assessed.

The researchers examined all adult emergency admissions for community-acquired pneumonia between 1 January 2018 and 31 December 2023 at two Australian hospitals. Data were captured from electronic medical records using the International Classification of Diseases. Patients were classified as non-frail if their HFRS was below 5 and as frail if the score was 5 or above.

The cohort comprised 6,885 patients with a mean age of 75.4 years (standard deviation 17.4), and 54.7 percent were male. The mean HFRS was 5.3 (standard deviation 4.8), and 41.7 percent of patients were classified as frail.

Using multilevel multivariable regression analysis, the team tested whether the score predicted a range of clinical outcomes: length of hospital stay, risk of intensive care unit admission, in-hospital mortality, 30-day and 365-day mortality, and 30-day readmission risk.

Each increasing point on the HFRS significantly predicted a longer hospital stay, with an incidence rate ratio of 1.07, and a greater likelihood of ICU admission, with an adjusted odds ratio of 1.12. Higher scores were also associated with higher in-hospital mortality (adjusted odds ratio 1.06), higher 30-day mortality (adjusted odds ratio 1.05) and higher 365-day mortality (adjusted odds ratio 1.02), with p values of 0.001 or less for all of these outcomes.

By contrast, the HFRS was not significantly associated with the risk of readmission within 30 days of discharge, indicating that the score’s predictive value in this cohort was limited to the in-hospital and early and longer-term mortality outcomes and to resource use measures such as length of stay and ICU admission.

The authors conclude that the HFRS is a practical, low-cost tool which could have far-reaching implications for streamlining clinical care worldwide, and that the evidence for its use is becoming more robust with each subsequent validation study. As a retrospective observational analysis of administrative data from two hospitals, the study establishes associations between the score and outcomes in this population rather than demonstrating that the score itself changes care, and the findings apply to the Australian pneumonia cohort studied. The work adds Australian evidence to a growing body of validation studies of the score, which has previously been examined in other settings, including critically ill patients and older adults receiving mechanical ventilation.

Subject of Research: External validation of the Hospital Frailty Risk Score for predicting clinical outcomes in patients hospitalised with community-acquired pneumonia in Australia

Article Title: External validation of the hospital frailty risk score for predicting clinical outcomes in patients hospitalised with community acquired pneumonia in two Australian hospitals

Article References: Hauser, M., Mangoni, A. A., Thompson, C., Horwood, C., & Sharma, Y. (2026). External validation of the hospital frailty risk score for predicting clinical outcomes in patients hospitalised with community acquired pneumonia in two Australian hospitals. Aging Clinical and Experimental Research. https://doi.org/10.1007/s40520-026-03518-w

Image Credits: AI Generated

DOI: 10.1007/s40520-026-03518-w

Keywords: frailty, Hospital Frailty Risk Score, community-acquired pneumonia, hospitalisation, mortality, length of stay, ICU admission, risk stratification, older adults, retrospective study, Australia, External

News Source: Beatrice Stafford. (October 29, 2026). Frailty score predicts outcomes in Australian pneumonia patients, study finds. Scienmag.

Tags: Australiacommunity-acquired pneumoniaexternalFrailtyHospital Frailty Risk ScorehospitalisationICU admissionlength of staymortalityolder adultsRetrospective studyrisk stratification
Share12Tweet7Share2ShareShareShare1

Related Posts

ZNF207 shields glutamine transporter ASCT2 from degradation to fuel liver cancer growth

ZNF207 shields glutamine transporter ASCT2 from degradation to fuel liver cancer growth

October 30, 2026
Most Ethiopian HIV patients on dolutegravir therapy show good knowledge, survey finds

Most Ethiopian HIV patients on dolutegravir therapy show good knowledge, survey finds

October 30, 2026

Serum and urine protein biomarkers may sharpen prostate cancer detection beyond PSA

October 30, 2026

One gene locus flags atrial fibrillation risk after major surgery, UK Biobank study finds

October 30, 2026

POPULAR NEWS

  • Microbial Sources and Stress Shape the Hidden Endophytes of an Invasive Plant

    Microbial Sources and Stress Shape the Hidden Endophytes of an Invasive Plant

    29 shares
    Share 12 Tweet 7
  • Firebreaks Leave Lasting Scars in Grasslands While Wildfire Heals Fast

    29 shares
    Share 12 Tweet 7
  • ZNF207 shields glutamine transporter ASCT2 from degradation to fuel liver cancer growth

    29 shares
    Share 12 Tweet 7
  • Systematic review maps sustainability tensions in offshore wind development

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Microbial Sources and Stress Shape the Hidden Endophytes of an Invasive Plant

Firebreaks Leave Lasting Scars in Grasslands While Wildfire Heals Fast

ZNF207 shields glutamine transporter ASCT2 from degradation to fuel liver cancer growth

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 86 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.